Intellia Therapeutics

Intellia Therapeutics

Yahoo Finance • 13 days ago

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Choosing between Intellia Therapeutics (NASDAQ:NTLA) and Omeros (NASDAQ:OMER) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan disease treatments. Intellia Therapeutics... Full story

Yahoo Finance • 15 days ago

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas inclu... Full story

Yahoo Finance • 16 days ago

What Makes BioLife Solutions (BLFS) a Compelling Long-Term Hold?

Prosper Stars & Stripes, a long/short equity fund, recently released its first-quarter 2026 investor letter. A copy of the letter is available to download here. In Q1 2026, the portfolio underperformed with a net return of (-5.6%) compared... Full story

Yahoo Finance • 21 days ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026 HAELO manuscript simultaneously published in the New England Journal of Medici... Full story

Yahoo Finance • 28 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today ann... Full story

Yahoo Finance • last month

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Investors have long looked to Warren Buffett for investing inspiration. This is because the billionaire, as chief executive officer of Berkshire Hathaway for 60 years, led the company to market-beating returns over that time period. He did... Full story

Yahoo Finance • last month

Draft FDA guidance could be a boon for gene therapy developers

[Genetic Medicine And DNA Therapy] narvo vexar * The US FDA has issued draft guidance intended to accelerate the development of gene and cell therapies. * The agency hopes the document will enhance the R&D process for the treatments "... Full story

Yahoo Finance • last month

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today ann... Full story

Yahoo Finance • 2 months ago

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital raised the price target for Nextpowe... Full story

Yahoo Finance • 2 months ago

Intellia Therapeutics GAAP EPS of -$0.81 beats by $0.08, revenue of $15.04M beats by $1.23M

* Intellia Therapeutics press release [https://seekingalpha.com/pr/20508834-intellia-therapeutics-announces-first-quarter-2026-financial-results-and-business-updates] (NTLA [https://seekingalpha.com/symbol/NTLA]): Q1 GAAP EPS of -$0.81 b... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $12.9 million of tumbling tech stock

Cathie Wood, chief of Ark Investment Management, is known for making bold bets on fast-moving tech stocks. Sometimes her trades move just as quickly as the stocks themselves. In the week that began on May 3, Wood sold millions of dollars... Full story

Yahoo Finance • 2 months ago

Cathie Wood Dumps $72 Million of AMD, Doubles Down on Alphabet and Meta

This article first appeared on GuruFocus. Cathie Wood's ARK Invest shifted cash into several large-cap technology names and AI-linked growth stocks while trimming exposure to semiconductors and crypto-related products, according to the fu... Full story

Yahoo Finance • 2 months ago

Cathie Wood Loads Up $14 Million on Alphabet Just Before Earnings

This article first appeared on GuruFocus. Cathie Wood's ARK Invest funds bought Alphabet (NASDAQ:GOOGL), CoreWeave (NASDAQ:CRWV), Intellia Therapeutics (NTLA) and Kratos Defense & Security Solutions on Tuesday, while trimming Bullish (NYS... Full story

Yahoo Finance • 2 months ago

Intellia Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today an... Full story

Yahoo Finance • 2 months ago

Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying.

Intellia Therapeutics could soon win Food and Drug Administration approval for the first-ever drug that edits genes inside a patient's body. Continue Reading... Full story

Yahoo Finance • 2 months ago

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

World’s first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq... Full story

Yahoo Finance • 3 months ago

The Credibility Filter Wall Street Uses to Sort Biotech Winners

VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinic... Full story

Yahoo Finance • 4 months ago

This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?

Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics(NASDAQ: NTLA), fits the bill. Intellia is a mid-ca... Full story

Yahoo Finance • 4 months ago

Roblox initiated, Target upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Telsey Advisory upgraded Target (TGT)... Full story

Yahoo Finance • 4 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood seems to always be making market moves. The founder and CEO of Ark Invest publishes her transactions at the end of every trading day, and that gives us all a great way to track one of the most widely followed growth investors.... Full story